The experimental work of the Myeloma Lymphoma Research group includes a broad spectrum of research activity, mainly focusing on multiple myeloma. Clinical haematologists from the Haemato-Oncology Unit and non-clinical researchers from Champalimaud Research work together to expand their knowledge of the biology of lymphoid neoplasms and improve their treatment.
Multiple myeloma (MM) is the third most common haematological malignancy and is characterised by multi-focal proliferation of monoclonal plasma cells in the bone marrow (BM). In the last two decades, novel therapies have considerably increased patient survival. Still, 48% of patients succumb to MM within five years after diagnosis. This poor prognosis is mostly related to the difficulty in making an accurate diagnosis and to the lack of treatments able to eliminate residual myeloma cells. Thus, there is an important unmet need for development of new diagnosis and therapeutic strategies for this complex disease. The group is tackling these challenges from complementary approaches through the following projects: